α-Tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis  by Tomasetti, Marco et al.
FEBS Letters 580 (2006) 1925–1931a-Tocopheryl succinate induces DR4 and DR5 expression by a
p53-dependent route: Implication for sensitisation of resistant cancer
cells to TRAIL apoptosis
Marco Tomasettia,*, Ladislav Anderab, Renata Allevac, Battista Borghic, Jiri Neuzilb,d,
Antonio Procopioa,e
a Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, via Ranieri 1, Ancona, Italy
b Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Czech Academy of Sciences, Czech Republic
c Department of Anaesthesiology, IRCCS Orthopaedic Institute ‘‘Rizzoli’’, Bologna, Italy
d Apoptosis Research Group, School of Medical Science, Griﬃth University, Southport, Qld., Australia
e Center of Cytology, Italian National Research Center on Aging (INRCA-IRCCS), Ancona, Italy
Received 16 December 2005; revised 17 February 2006; accepted 21 February 2006
Available online 28 February 2006
Edited by Varda RotterAbstract We evaluated the ability of a-tocopheryl succinate (a-
TOS) to sensitise TRAIL-resistant malignant mesothelioma
(MM) cells to TRAIL-induced apoptosis. We show that a-
TOS activates expression of DR4/DR5 in a p53-dependent man-
ner and re-establishes sensitivity of resistant MM cells to
TRAIL-mediated apoptosis, as documented in p53wt MM cells
but not in their p53null counterparts. MM cells selected for
TRAIL resistance expressed low cell surface levels of DR4 and
DR5. Treatment with sub-lethal doses of a-TOS restored
expression of DR4 and DR5. The ability of a-TOS to modulate
expression of pro-apoptotic genes may play a role in sensitisation
of tumour cells to immunological stimuli.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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DR5; DR41. Introduction
a-Tocopheryl succinate (a-TOS), an analogue of vitamin E,
is a potent inducers of apoptosis and inhibits proliferation of
several malignant cells [1–4]. a-TOS induces a variety of con-
centration-dependent cellular events. More speciﬁcally, it mod-
ulates signalling pathways in various in vitro models, in
general in the 10–30 lM range, while its cytotoxic eﬀect be-
comes prominent at higher concentrations [5]. Studies have
shown that a-TOS induces cancer cells to undergo apoptosis
via at least three pathways, i.e., the transforming growth fac-
tor-b (TGF-b), the c-jun N-terminal kinase (JNK) mitogen-
activated protein kinase (MAPK), and the tumour necrosis
factor (TNF) signalling pathway [6–8]. Upregulation of FasAbbreviations: DR, death receptor; FLIP, FLICE inhibitory protein;
MM, malignant mesothelioma; ActD, actinomycin D; Q-PCR, quan-
titative real-time PCR; siRNA, small interfering RNA; a-TOS, a-
tocopheryl succinate; TR, TRAIL-resistant; TRAIL, TNF-related
apoptosis-inducing ligand
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doi:10.1016/j.febslet.2006.02.054ligand expression was observed in Fas-insensitive human
breast cancer cells followed by a-TOS treatment sensitising
them to the immunological agent [8].
Among the TNF ligand members, TNF-related apoptosis-
inducing ligand (TRAIL) has recently drawn considerable
interest as a potential eﬀective anti-tumour therapeutic agent,
in particular since, in contrast to the Fas ligand toxic to nor-
mal cells, TRAIL appears largely selective for malignant cells
[9,10]. TRAIL, present on the surface of immune cells as a type
II membrane protein or secreted in a soluble form, mediates
apoptosis in sensitive cells by binding to their cognate death
receptors (DRs), DR4 and DR5 [11,12]. Although both DRs
are widely expressed in human tissues, some cancer cells are
insensitive to TRAIL-mediated killing [13–15].
Heterogeneous sensitivity of tumour cells to TRAIL-
induced apoptosis has been observed in malignant mesotheli-
oma (MM) [16], which may lead to a persistent growth of
TRAIL-resistant cells, and may limit successful treatment of
the neoplastic disease by TRAIL. Notably, MM is an aggres-
sive and treatment-resistant tumour with currently only pallia-
tive cure [17].
Here, we investigated the ability of a-TOS to ‘convert’
TRAIL-resistant MM cells to TRAIL-responsive ones by
inducing trans-activation of DR4 and DR5. In order to evalu-
ate the involvement of p53, MM cell lines diﬀering in their p53
status were used. a-TOS exerted diﬀerential eﬀects on p53wt
and p53null cells, and activated p53 that, in turn, induced
expression of DRs, leading to increased sensitivity to
TRAIL-induced apoptosis. Our data suggest that upregulation
of cell surface DR expression induced by a-TOS may contrib-
ute to a shift in the anti- and pro-apoptotic signals in favour of
the latter, triggering apoptotic signals.2. Materials and methods
2.1. Reagents
a-Tocopheryl succinate (a-TOS), actinomycin D (ActD), and annex-
in V–FITC were purchased from Sigma (St. Louis, MO, USA). Soluble
human recombinant TRAIL (hrTRAIL) was prepared as described
elsewhere [18]. Anti-DR4 and anti-DR5 monoclonal IgGs were
obtained from Alexis Biochemicals (Lausen, Switzerland). Anti-
phospho-p53 (Ser-20) IgGs were from Cell Signalling Technology,blished by Elsevier B.V. All rights reserved.
1926 M. Tomasetti et al. / FEBS Letters 580 (2006) 1925–1931Inc. (Beverly, MA, USA). Anti-p53 (Ab-6) IgG was obtained from
Calbiochem (San Diego, CA, USA). All primers for RT-PCR were ob-
tained from Sigma Genosys (St. Louis, MO, USA). Foetal bovine ser-
um was obtained from EuroClone (Paignton, UK).
2.2. Cell culture
The wild-type p53 (p53wt) MM-B1, Meso-2, and Ist-Mes human
MM cell lines [19] and the p53-deﬁcient (p53null) REN human MM
cells were used. REN cells were a generous gift from Steven Albelda,
University of Pennsylvania Medical Centre, Philadelphia, PA, USA.
Cells were cultured in the RPMI-1640 medium supplemented with
2 mM L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin, and
10% FBS.
2.3. Apoptosis detection
Apoptosis was quantiﬁed using the annexin V–FITC method, which
detects phosphatidyl serine (PS) externalised in the early phases of
apoptosis [20]. Brieﬂy, cells were plated at 105 per well in 24-well
plates. After an overnight incubation, cells were treated with a-TOS
(30 lM) or hrTRAIL (10 ng/ml) alone or in combination. Floating
and attached cells were collected, washed twice with PBS, re-suspended
in 0.1 ml binding buﬀer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl2,
pH 7.4), incubated for 20 min at room temperature with 2 ll annexin
V–FITC, supplemented with 10 ll of propidium iodide (PI) (10 lg/
ml), and analysed by ﬂow cytometry (FACScalibur), using channel 1
for annexin V–FITC binding and channel 2 for PI staining.
2.4. Selection of TRAIL-resistant MM cells
Selection of TRAIL-resistant cells was performed as previously de-
scribed [21]. The p53wt MM-B1 cells were seeded in a 6-well plate at
the concentration of 2 · 105 cells/well (60% of conﬂuence) and treated
with 200 ng/ml TRAIL for 24 h resulting in 30–40% cell death. The
apoptotic cells were removed and surviving cells were fed every day
for 5–6 weeks with culture medium containing TRAIL (200 ng/ml) un-
til they reached 70–80% conﬂuence. The resulting cells were then cul-
tured in the presence of TRAIL (10 ng/ml) and subsequently
examined for expression of apoptosis modulators including DR4,
DR5, FLIP and caspases, as well as for their sensitivity to TRAIL-in-
duced cell death by the annexin V–FITC assay.
2.5. Western blot analysis
Cells were treated as indicated and lysed in a buﬀer containing
250 mM NaCl, 25 mM Tris–HCl (pH 7.5), 5 mM EDTA (pH 8), 1%
Nonidet P-40, and a cocktail of protease inhibitors (2 lg/ml aprotinin,
2 lg/ml leupeptin, 1 mM phenylmethyl-sulfonyl ﬂuoride and 2 lg/ml
proteinin) and stored at 80 C until analysis. Protein level was quan-
tiﬁed using the Bradford assay (Sigma). Protein samples (80 lg per
lane) were boiled for 5 min and resolved using 12.5% SDS–PAGE,
and transferred to a nitrocellulose membrane. The membrane was
blocked (PBS containing 0.1% Tween and 5% skimmed milk) for
1 h, and incubated overnight with anti-DR4, anti-DR5, anti-p21,
anti-p53 or anti-phospho-p53 (ser-20) IgG. After incubation with an
HRP-conjugated secondary IgG (Amersham, London UK), the blots
were developed using the ECL kit (Pierce, Rockford, IL, USA). Pro-
tein loading was corrected for using anti-b-actin IgG.2.6. Small interfering RNA (siRNA) transfections
siRNA duplex oligonucleotides, sense 5 0-GCA UGA ACC GGA
GGC CCA-3 0-dTdT, anti-sense 5 0-AUG GGC CUC CGG UUC
AUG C-3 0-dTdT, corresponding to the target sequence CGG CAU
GAA CCG GAG GCC CAU of p53, were used to inhibit p53 protein
expression. As a negative control, a non-silencing (NS) RNA was used:
sense 5 0-UUC UCC GAA CGU GUC ACG U-30-dTdT, anti-sense 5 0-
ACG UGA CAC GUU CGG AGA A-3 0-dTdT (all siRNAs from Qia-
gen, Hilden, Germany). The oligonucleotide pairs were dissolved in the
suspension buﬀer (100 mM potassium acetate, 30 mM HEPES-KOH,
2 mM magnesium acetate, pH 7.4) and annealed by incubation for
2 min at 95 C. MM-B1 cells were seeded into 6-well plates at 105
per well and transfected with the oligonucleotides according to the
manufacturer’s instructions. Brieﬂy, 10 ll of siRNA (5 lg) was dis-
solved in 100 ll of the cell culture medium and supplemented with
15 ll of RNAiFect (Qiagen). The solution was incubated for 30 min
at room temperature and added to each well containing 1.9 ml of med-ium. Cells were incubated for 6 h prior to the addition of 2 ml of fresh
medium. After 48 h of incubation, p53 expression was evaluated by
Western blotting.
2.7. RT-PCR and quantitative real-time mRNA analysis
Total RNA was isolated from 106 MM cells before and after treat-
ment with 30 lM a-TOS using Trizol (Life Technologies, Rockville,
MD, USA) according to the manufacturer’s protocol. The ﬁrst-strand
cDNA was synthesized using the GeneAmp RNA PCR kit (Perkin–El-
mer Life Sciences, Boston, MA, USA). PCR analyses were performed
in the ﬁnal volume of 20 ll of buﬀer containing 1 ll of the retro-tran-
scription product, dNTPs (150 lM each), MgCl2 (2 mM), 1 U of Taq
Gold polymerase (Roche Molecular Biochemicals, Basel, Switzerland),
and each primer at 1 lM. The house-keeping gene b-actin was used as
a loading control.
Relative quantiﬁcation of mRNA expression was achieved by quan-
titative real time-PCR (Q-PCR). The technique is based on the detec-
tion of a ﬂuorescent signal produced by incorporation of the
ﬂuorescent dye SYBR-green (DyNamoHS, Finnzymes, Espoo, Fin-
land) during PCR ampliﬁcation (Chromo 4tm Detector, MJ Research,
Waltham, MA, USA). The sequences of the primers were published
elsewhere [22]. Expression of DR4 and DR5 was normalized to b-ac-
tin. The increase of DR mRNA in a-TOS-treated cells with respect
to the control (untreated cells) was determined using the formula:
X ¼ 2DDct ; DDct = dE  dC; dE = n cycles of DR gene – n cycles
of house-keeping gene in the treated cells; dC = n cycles of DR gene
n cycles of house-keeping gene in the control cells.
2.8. Flow cytometric detection of DR expression
Expression of DR4 and DR5 was evaluated by ﬂow cytometry be-
fore and after treatment with a-TOS (30 lM). MM cells were seeded
24 h before the treatment in 6-well plates at 3 · 105 per well. After
16 h of incubation, ﬂoating and attached cells were collected, washed
twice with PBS, incubated at 4 C with antibodies against DR4 and
DR5 followed by a secondary FITC-conjugated IgG, and then ana-
lysed by ﬂow cytometry. Cytoplasm expression of TRAIL receptors
was assessed after cell permeabilisation. Brieﬂy, cells were ﬁxed in
4% formaldehyde in PBS for 30 min, washed, permeabilised with a sap-
onine solution (0.2% saponine in PBS plus 1% FCS) for 30 min, incu-
bated with the antibodies as described above, and assessed by ﬂow
cytometry.2.9. Immunocytochemistry
Parental MM-B1 cells and their TRAIL-resistant (TR-1) counter-
parts were placed overnight in 35-mm dishes on poly-L-lysine-coated
glass cover-slips. After 6 h of incubation with a-TOS (30 lM), the cells
were washed 2-times with PBS, ﬁxed with 4% formaldehyde in PBS,
and incubated with (permeabilised cells) or without (intact cells) a sap-
onine solution (0.05% saponine and 2% FCS in PBS). Cells were then
incubated with mouse anti-human phospho-p53 (Ser-20), DR4 or DR5
IgG for 1 h at room temperature. FITC-conjugated, anti-mouse sec-
ondary IgG was added. The cover-slips were mounted on glass slides
with VectaShield plus DAPI (Vector Laboratories, Burlingame, CA,
USA) and inspected in a confocal microscope (BioRad, MRC 1024,
Hercules, CA, USA).2.10. Transcriptional inhibition and cytotoxicity analysis
For the inhibition experiments the MM cells were incubated with
actinomycin D (ActD) which is generally used as an inhibitor of tran-
scription [23].
MM cells were plated in 96-well ﬂat-bottom tissue culture plates at
104 per well. The cells were incubated overnight with ActD at ﬁnal con-
centration of 5 lM dissolved in DMSO (0.5%) or DMSO alone (0.5%).
To remove unincorporated ActD, the treated cells were washed three
times with RPMI-1640 and then incubated for 24 h with a-TOS and
TRAIL at 30 lM and 10 ng/ml, respectively, alone or in combination.
DR4 and DR5 gene expression was evaluated by RT-PCR performed
as described above. Cytotoxicity was determined by using the MTT as-
say [24]. Brieﬂy, following cell treatment, 10 ll of MTT (5 mg/ml in
PBS) was added, and after incubation for 4 h at 37 C, the medium
was removed and combined with 200 ll of 1% SDS. Absorbance was
read at 550 nm using an ELISA plate reader with control absorbance
set at 100%.
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All experiments were conducted at least three times, and data are
shown as means ± S.D. Signiﬁcance was evaluated by the ANOVA re-
peated measure test. Data were considered statistically signiﬁcant at
P < 0.05.3. Results and discussion
The p53 protein is a key component of the cellular ‘emer-
gency-response’ mechanism [25,26]. The most studied function
of p53 is its role as a transcription factor that can activate tran-
scription of an ever-increasing number of target genes [27,28].
A recent paper reported that p53 can also act as an anti-
oxidant protein [29]. A variety of stress-associated signals
activate p53 that induces growth arrest or apoptosis, thereby
eliminating damaged and potentially dangerous cells [30].
Here, we assessed the ability of a-TOS to induce transcrip-Fig. 1. Eﬀect of a-TOS exposure on the level of p53. (A) MM-B1 cells
(as representative of p53wt MM cells), were incubated with a-TOS at
sub-apoptotic doses (20 and 30 lM) for 24 h. Cell lysates were
subjected to Western blotting using p53, phospho-p53 (Ser-20), p21
and b-actin antibodies. (B) MM-B1 cells were grown on cover-slips,
and treated for 6 h with a-TOS (30 lM). Cells were then incubated
with anti-phospho-p53 (Ser-20) IgG, and after incubation with FITC-
conjugated secondary IgG, the cover-slips were mounted on glass
slides with Vectashield plus DAPI and observed in a confocal
microscope. Results shown are representative of three independent
experiments.tional activation of the pro-apoptotic genes DR4 and DR5
by a p53-dependent route. Exposure of p53wt MM cells to
sub-toxic doses of a-TOS induced expression and activation
of p53. The level of p53 phosphorylated on Ser-20 increased
in a dose-dependent manner (Fig. 1A and B). Activation of
p53 was associated with expression of DR4 and DR5 as re-
vealed by Q-PCR. Notably, such expression of DRs was not
observed in the p53null REN cells and was abrogated in
p53wt MM cells when p53 expression was partially silenced
by siRNA (Fig. 2A). The ﬂow cytometric analysis, performed
on both intact and permeabilised cells, and the Western blot
assay revealed that sub-lethal doses of a-TOS increased expres-
sion of the DR4 and DR5 protein, which was not observed in
MM cells lacking normal expression of p53 (Table 1, Fig. 2B).
DR5 and, more so, DR4 play a critical role in mediating
TRAIL-induced apoptosis. It has been recently reported that
siRNA targeting of DR5 was ineﬀective at blocking TRAIL-
induced apoptosis, whereas siRNA-mediated knock-down of
DR4 conferred protection against TRAIL-induced cell killing
[31]. Further, MM cells exert heterogeneous sensitivity to
TRAIL-induced cell death, even though both DR4 and DR5
are endogenously expressed on their cell surface [16]. By pro-
longed exposure to TRAIL, we generated TRAIL-resistant
MM cells (TR-1). The TRAIL-resistant population wasFig. 2. Eﬀect of a-TOS treatment on the level of TRAIL death
receptors in MM-B1 and REN cells. (A) DR4 and DR5 were evaluated
in p53wt MM-B1, MM-B1siRNA (p53 siRNA was used to inhibit p53
protein expression), and p53null REN cells as mRNA expression by Q-
PCR before and after treatment with 30 lM a-TOS for 4 h. (B) DR4
and DR5 protein expression in p53wt MM-B1 and p53null REN cells
before and after treatment with a-TOS (0, 20, and 30 lM) for 24 h. b-
Actin was used as a loading control. Results are representative of three
independent experiments.
Table 1
Evaluation of cytoplasmic and cell surface expression of TRAIL death receptors before and after a-TOS treatment in MM-B1 and REN cells
Cell type Intact Permeabilised
DR4 DR5 DR4 DR5
Ctrl a-TOS Ctrl a-TOS Ctrl a-TOS Ctrl a-TOS
MM-B1 1.9 ± 0.2 2.2 ± 0.3 8.1 ± 0.4 10.1 ± 0.5* 3.4 ± 0.1 5.2 ± 0.2* 15.0 ± 0.6 17.1 ± 0.4*
REN 1.8 ± 0.3 1.8 ± 0.2 8.4 ± 0.6 8.6 ± 0.4 1.9 ± 0.1 2.2 ± 0.2 10.4 ± 0.4 11.3 ± 0.3
Expression of DR4 and DR5 was evaluated by ﬂow cytometry before (Ctrl) and after treatment with a-TOS (30 lM, 16 h) in p53wt MM-B1 and
p53null REN cells. The values represent ﬂuorescence intensity of the receptors normalized for a blank incubated with an irrelevant primary antibody.
Data are expressed as means ± S.D. from three independent experiments and statistical diﬀerences between controls versus a-TOS treatment are
marked with the  symbol, P < 0.05.
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sion of DR5 was observed when compared to their parental
counterparts (Fig. 3A, top panel). Interestingly, exposure to
a-TOS (30 lM) signiﬁcantly enhanced both cytosolic and cell
surface expression of both DR4 and DR5 in TRAIL-resistant
cells as evaluated by cytometry (Fig. 3A, lower panel) and con-
focal microscopy (Fig. 3B).
Elevated expression of the TRAIL DRs resulted in a syner-
gistic and cooperative a-TOS/TRAIL eﬀect, which was ob-
served only in MM cells and in selected TRAIL-resistant
MM cells (TR-1) with functional p53 (Fig. 4A). Thus, p53-Fig. 3. Expression of DR4 and DR5 in selected TRAIL-resistant cells an
Expression of DR4 and DR5 in parental p53wt MM-B1 and selected TRAIL-
TRAIL-resistant (TR-1) cells before and after a-TOS (30 lM) exposure (bot
then labelled with anti-DR4 or anti-DR5 antibody followed by labelling wit
confocal microscopy (B). Images representative of three independent experimdependent up-regulation of TRAIL’s DRs is required for sen-
sitisation of MM cells to TRAIL-induced apoptosis. It has
been demonstrated that activation of p53 is a prerequisite for
restoration of TRAIL sensitivity in colon carcinomas [32],
and p53-dependent upregulation of DR4 and DR5 expression
has been observed [33,34]. Moreover, it has been reported that
p53 directly regulates transcription of the DR4 gene via an in-
tronic sequence-speciﬁc p53 binding-site [35].
To investigate whether the synergistic and cooperative a-
TOS/TRAIL eﬀect was related to the transcriptional activation
of the TRAIL’s DR genes as a response to a-TOS treatment,d their parental counterpart before and after a-TOS exposure. (A)
resistant (TR-1) cells (top panel). DR4 and DR5 expression in selected
tom panel). The cells were or were not permeablised (intact cells) and
h FITC-conjugated antibody and analysed by ﬂow cytometry (A), and
ents are shown.
Fig. 4. (A) Cytotoxic eﬀect of hrTRAIL and a-TOS alone and their combination in p53wt/p53null MM cell lines. MM cells were seeded into 24-well
tissue culture plates (105 per well) and treated for 24 h with hrTRAIL (10 ng/ml) and a-TOS (30 lM) alone or in combination. Apoptosis induction
was evaluated by annexin-V–FITC. (B) Cytotoxic eﬀect of hrTRAIL and a-TOS alone and their combination in p53wt MM cells incubated with and
without actinomycin D (ActD, right panel). MM cells were plated in 96-well ﬂat-bottom tissue culture plates at 104 per well. The cells were incubated
overnight with ActD at ﬁnal concentration of 5 lM (dissolved in DMSO) or DMSO alone. Unincorporated ActD was removed by washing the cells
with RPMI-1640, and the cells were then incubated for 24 h with a-TOS (30 lM) and TRAIL (10 ng/ml) alone or in combination. DR4 and DR5
mRNA transcripts were evaluated by RT-PCR performed as described under Section 2 (left panel). Cytotoxicity was determined using the MTT
assay. *The combined eﬀect was signiﬁcantly greater than the eﬀects of individual agents, P < 0.05. Results are expressed as means ± S.D. from three
independent experiments.
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itor actinomycin D (5 lM), then incubated with a-TOS and
TRAIL alone or in combination. DR4 and DR5 gene expres-
sion and cytotoxicity were evaluated. As shown in Fig. 4B (left
panel), a-TOS-exposed cells pre-treated with actinomycin D
failed to accumulate TRAIL’s DR transcripts, whereas levels
in untreated cells were increased over the control for both
DR4 and DR5 at 4 h of a-TOS treatment. Thus, inhibition
of TRAIL’s DR gene expression suppresses the cooperative
TRAIL/a-TOS eﬀect as observed in Fig. 4B (right panel).
Apoptosis induced by death receptors can be modulated at
several levels. Intracellular anti-apoptotic molecules can block
the apoptotic signalling pathway or divert them towards alter-native responses. Such molecules include the cellular FLICE-
like inhibitory protein (c-FLIP), which competes with cas-
pase-8 for binding to FADD [36], or XIAP, cIAP-1 and
cIAP-2, that directly inhibit caspase activity. A role of FLICE
inhibitory protein (FLIP) in inhibiting TRAIL-induced cell
death has been previously observed in MM cells [15]. Upregu-
lation of TRAIL death receptors by a-TOS may contribute to
a shift in the anti- and pro-apoptotic signals in favour of the
latter, triggering apoptotic signals, which may then be
ampliﬁed by the intrinsic pathway. Kinetics of analysis of
TRAIL-induced signalling revealed a transient activation of
caspase-8, which resulted in induction, albeit low, of apoptosis.
Caspase-8 activation was less pronounced in the presence of
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chondria-dependent apoptotic pathway, including Bid cleav-
age, cytochrome c cytosolic mobilisation and, ﬁnally,
caspase-9 activation, was observed [16]. Bid cleavage may lead
to mitochondrial translocation of Bax, as shown for a-TOS in
other cancer models [37,38]. Thus, the elevation of p53 in re-
sponse to a-TOS could facilitate TRAIL-induced apoptosis
by inducing transcription of TRAIL death receptors, whose
engagement by the ligand causes activation of caspase-8,
releasing both Bid and Bax from their sequestration by Bcl-
xL, promoting mitochondrial-dependent apoptosis.
In the present study, we demonstrate the ability of a-TOS, a
redox-silent analogue of vitamin E, to enhance or restore
TRAIL sensitivity by upregulating its death receptors in
MM cells. We show that a-TOS upregulated DR4 and DR5
in p53wt MM cells but not in MM cells lacking functional
p53 and that the eﬀect was more evident in TRAIL-resistant
MM cells deﬁcient in DR4 and DR5 as compared to the paren-
tal p53wt MM cells.
Reversal of TRAIL resistance in cancers like mesothelioma
by a-TOS appears to be a viable strategy and is expected to im-
pact on the future on anti-cancer therapeutic approaches, in
particular taking into consideration strong anti-mesothelioma
activity of the vitamin E analogue [39,40] and the current lack
of other than palliative treatment of MM [17].
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